IMMUNOLOGY2026™ Conference Recordings For Attendees-Combination XPO1/PD1 inhibition for canine cutaneous T cell lymphoma: a comparative oncology approach

Combination XPO1/PD1 inhibition for canine cutaneous T cell lymphoma: a comparative oncology approach

Video Transcription

Video Summary

Celia Mundt presented a Tufts study on canine cutaneous T cell lymphoma (CTCL), a skin-based cancer that is often mistaken for benign dermatitis and diagnosed late. Using targeted transcriptomics, her team identified biomarkers that distinguish CTCL from inflammatory skin diseases. They then tested a combination of an XPO1 inhibitor and PD-1 blockade in six dogs: two achieved complete responses, two partial responses, and two progressed. Tape strips showed promise as a less invasive diagnostic tool, and blood analyses suggested immune reprogramming during treatment. The work supports canine CTCL as a model for aggressive human CTCL and for future combination therapies.

Meta Tag

Date April 17, 2026 5:15 PM - 5:30 PM

Room 104AB

Session Learning from Others - Immunity from the Jawless to Paws and Hooves

Speaker Celia Mundt

Track Veterinary and Comparative Immunology (VET)

Year 2026

Keywords

canine cutaneous T cell lymphoma

CTCL biomarkers

targeted transcriptomics

XPO1 inhibitor PD-1 blockade

tape strip diagnostics

April 17, 2026 5:15 PM - 5:30 PM

104AB

Learning from Others - Immunity from the Jawless to Paws and Hooves

Celia Mundt

Veterinary and Comparative Immunology (VET)

2026